MSC Organized “If Pacemakers Could Talk” in Nanchang

Jiangxi, China, 21 June 2021 — Recently, MicroPort SoaringCRM (MSC), successfully held an event themed, ‘If Pacemakers Could Talk’, in Nanchang, Jiangxi. Experts from Jiangxi Provincial People’s Hospital among other medical institutions were invited to share their clinical experience and perspective on the future direction of Chinese-manufactured pacemakers.

The event was chaired by Prof. Ming Hong of Jiangxi Provincial People’s Hospital, Prof. Xinchun Zhou of Shangrao People’s Hospital, Prof. Yuanqing Liu of Jiangxi Provincial People’s Hospital and Prof. Xiaohua Zeng of Xingan County People’s Hospital. In presentations entitled ‘The New Concept of Physiological Pacing’, ‘Intelligent Management of AVB with SafeR’ and ‘Effective Reduction of Unnecessary Ventricular Pacing using Dplus’, the professors introduced clinical applications of SafeR to manage cases of patients with AVB and other conditions that require pacemakers.

In his opening speech, Prof. Lang Hong of Jiangxi Provincial People’s Hospital said, “Pacing therapy has been available for more than 60 years, and pacemaker implantation techniques are becoming increasingly sophisticated. With the continuous evolution of pacemaker devices, there are numerous emerging features and algorithms. Clinicians need to master not only implantation techniques but also pacemaker functions to treat their patients better. ”

In the presentation session themed, ‘A small device for longer life’, Prof. Yuliang Chai from Jiangxi Provincial People’s Hospital, Prof. Dongming Xie from the First Affiliated Hospital of Gannan Medical University, Prof. Zhiwen Chen and Prof. Qiang Liu from Jiangxi Provincial People’s Hospital discussed the relationship between pacemaker size and life expectancy. Reducing power consumption extends the life of MSC pacemakers without increasing their size. Relying on optimal structural and interface design, the pacemakers reduce the risk of infection and are more suited to children or thin patients. These pacemakers also offer greater advantages as they use sensors to automatically determine patient status and adjust pacing frequency.

A pacemaker is an electronic therapeutic device implanted in the body to treat cardiac dysfunction caused by certain cardiac arrhythmias. Since its first implantation in 1958, the pacemaker has benefited millions of patients with bradycardia worldwide. With the rapid development of manufacturing technology and techniques, the functions of pacemakers have become increasingly sophisticated.

With the continuous development of implantable devices, the role of pacemakers has moved beyond just ensuring patients’ basal heart rate to include meeting their physiological needs. MSC’s Rega™ family of pacemakers are equipped with the SafeR physiological pacing feature and are able to ensure synchronized atrial pacing of patients with prolonged PR intervals. The minimal right ventricular pacing feature is well recognized for its ability to reduce the risk of atrial fibrillation and hospitalization due to heart failure.

Currently, there are about 1 million patients suffering from bradycardia in China, with about 300,000-400,000 new cases per year. However, only about 100,000 patients receive pacing therapy. As the average life expectancy increases, and with the aging of the population and the increasing acceptance of pacing therapy, a larger pool of elderly patients with arrhythmias will require pacemaker implantation to restore normal rates.

About MicroPort Soaring CRM

MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC) is a subsidiary of MicroPort Scientific Corporation (00853.HK). MSC has an aim to provide quality and affordable CRM products and services to patients in China. In the future, MSC will continue to factor in the clinical needs of patients and doctors in China and offer more targeted and refined cardiology treatment and management solutions. By promoting academic exchanges and sharing among clinicians, MSC is committed to promoting innovative solutions for more patients with heart disease.